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Sir,
We read with much interest the paper by Olsen et al (2005), in
which they observed an increased risk for early-onset breast cancer
in a follow-up study of the incidence of cancer in 1445 blood
relatives of 75 patients with Ataxia-Telangectasia diagnosed in
Denmark, Norway, Finland and Sweden. The results of this study
are supported by the unique study design in which AT patients
were identified from medical records, and relatives were identified
through population registry and validated for cancer, resulting in
60 years complete follow-up of the entire study population. The
excess risk for breast cancer was evident only in the mothers of
AT patients and they found no increase in breast cancer incidence
by increasing the probability of being a mutation carrier. Their
findings questioned the hypothesis of a causal relationship with
ATM heterozygosity, which is the assumption of a number of past
and ongoing studies (e.g. Bernstein et al, 2003).
Olsen et al mentioned that their findings were consistent with
our study showing that the risk for breast cancer among female
relatives seems to be restricted to the subgroup of obligate carriers
(Geoffroy-Perez et al, 2001). They also mentioned that mutation
carrier testing among families may bias the estimates by selective
testing of survivors and/or relatives affected by cancer. In our
French family study, we collected DNA samples from 401
individuals out of the 1423 relatives. This allowed us to classify
412 extra individuals as either carriers or noncarriers, allowing us
to classify 70% of the breast cancer cases (20 out of 28) and 56%
of the unaffected female relatives (300 out of 683). Therefore, we
wondered about the potential bias of the relative risk estimates due
to differential genotyping of cases compared to unaffected
relatives. Indeed, the overgenotyping of cases may have biased
the results towards the null hypothesis within the categories of
relatives with uncertain genotype, resulting in a lack of gradient in
breast cancer incidence in our study when using the ‘mixed
approach’ (Geoffroy-Perez et al, 2001). Therefore, we reanalysed
our data ignoring the genotyping (i.e. relatives were categorised
according to their a priori probability of being a mutation carrier,
i.e. the ‘a priori probabilities’ method) and using the correction for
genotyping as proposed in Olsen et al (2005) (i.e. the ‘corrected
mixed approach’). The main design feature of our study and the
genotyping of the AT locus have been previously described (Janin
et al, 1999). We estimated the standardised incidence ratio (SIR)
of breast cancer as for Cavaciuti et al (2005). For this letter, we
calculated the expected number of cancers per 5-year age category
using the updated French age-, sex- and period-specific (1978–
1982, 1983–1987, 1988–1992 and 1993–1997) estimated inci-
dences (Remontet et al, 2003).
The results showed that, although more precise, genotyping
(or the mixed approach) led to a point estimate of breast cancer
risk among carriers lower than that calculated using either the
a priori probabilities (SIR¼4.48) or the corrected mixed approach
(SIR¼5.13) (Table 1). Moreover, when using the a priori
probabilities, although none of the SIRs were significant, the
excess risk for breast cancer did not seem to be restricted to the
subgroup of carriers. Indeed, we found a gradient of breast cancer
incidence with increasing probability of being a mutation carrier.
We found an increased risk of breast cancer among relatives, with
a 12.5% probability of being a carrier. This was mostly explained
by an oversampling of the offspring of the AT patient’s great-aunts
or great-uncles when one of the offspring was diagnosed with
cancer (Table 2). When we excluded these offspring, we found a
P¼0.012 for the trend. In the corrected mixed approach, there
was no clear gradient of point estimate, even borderline, with a
P¼0.048 for the trend. The lack of gradient observed in the
corrected mixed approach may be because of a residual bias due to
the selective testing being insufficiently corrected by the method of
Olsen et al. Overall, using the method proposed by Thompson and
Easton (2001) to calculate the relative risk of breast cancer
associated with being a carrier, weighted with the a priori
probability of being a carrier, we found that the risk varied very
little irrespective of the method used (Table 1).
Similar to what was seen by Olsen et al, the association with
breast cancer in our study appeared particularly strong in the
group of mothers compared to aunts or grandmothers, even after
accounting for their 50% probability of being a carrier. We
estimated an SIR of 7.1 (95% CI: 1.4–21) (Tables 1 and 2), which
was similar to the SIR of 6.7 (95% CI: 2.9–13) found by Olsen et al.
However, we cannot rule out an association in the group of carrier
female relatives other than mothers. Indeed, the mixed approach
gave a significantly increased risk of breast cancer of 3.2 (95% CI:
1.2–6.9) and the corrected mixed approach gave an increased, but
not significant risk of 2.9 (95% CI: 0.04–16) (Table 1). None of the *Correspondence: Dr N Andrieu; E-mail: nadine.andrieu@curie.net
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group of carrier relatives other than mothers was very small for
both approaches. Surprisingly, the recently published study on
1160 relatives of 169 UK AT patients did not observe a significant
excess risk of breast cancer in mothers (SIR¼1.87; 95% CI: 0.61–
4.36). The highest excess risk observed in this study was in the
aunts (Thompson et al, 2005). However, the percentage of mothers
diagnosed with breast cancer in the UK study was particularly low
(3.8% against 2.1% expected) compared to either the Nordic study
(12.5% against 1.9% expected) or our study (8.1% against 1.1%
expected), suggesting low participation of families with an ill or
deceased mother.
Our findings are consistent with those of Olsen et al for a strong
association with breast cancer in the group of mothers. When
using an a priori probability approach, our findings were also
consistent with the existence of a possibly weaker association in
the group of carrier relatives other than mothers, and with the
existence of a gradient in breast cancer risk with increasing
probability of being a mutation carrier. Due to the small group
sizes, it is not clear whether the association found in mothers was
different from that found in carrier relatives other than mothers.
Both retrospective and prospective international studies could
help to determine whether or not mothers of AT patients have a
higher risk of breast cancer than that conferred by being an AT
heterozygote.
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Table 2 Breast cancer risk according to relationship to AT patient
Relationship to
AT patient No. PY Obs Exp SIR 95% CI
Mother 37 1559.5 3 0.42 7.14 1.44–20.9
All relatives except
mother
670 31167.4 25 18.53 1.35 0.87–1.99
Aunt 99 4033.6 2 1.26 1.59 0.18–5.73
Grandmother 65 4291.6 6 3.24 1.85 0.68–4.03
Grandaunt 158 9962.8 9 7.59 1.19 0.54–2.25
Great-grandmother 85 6374.2 5 5.34 0.94 0.30–2.19
Sister 28 475.9 0 0.03 —
Cousin 116 2032.7 0 0.12 —
Daughter of great-
aunt or -uncle
81 2712.9 3 0.45 6.67 1.34–19.5
Other relationship
a 38 1283.6 0 0.59 —
aFor example, great great grandmother, nephew.
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Sir,
Thank you for the opportunity to comment on this interesting
letter, which addresses some important methodological issues in
studies of risk factors with post hoc genotyping. In their collection
of French families in which one or more child is affected by AT,
d’Almeida and co-workers have shown how potential biases,
introduced by late genotyping of relatives with certain outcomes,
can be addressed by various analytical approaches. They then
compare and discuss the results.
In the Nordic study, genotyping of probands and parents
was generally completed during the diagnostic work-up of the
AT patients, that is, at the date of start of follow-up for subsequent
breast and other cancers. Supplementary genotyping of
other family members was usually conducted years or decades
later, either among survivors who were willing to participate or
among relatives who had died from breast cancer and for whom
tissue blocks were available. As the study hypothesis was
that carriers of an ATM allele are at increased risk for breast
cancer and perhaps other potentially deadly diseases, we
considered that we could not backdate the result of the gene
testing, that is, reallocate the person-years at risk from the start of
follow-up of these relatives, without running the risk of introdu-
cing differential misclassification. As the date of testing was not
available for all relatives, we decided not to change the gene
probability scores of the tested persons but only to change the
scores of their ancestors. We thus chose to retain some random
gene exposure misclassification due to the initial allocation of
carrier probability, defined by location in a family, rather than risk
introducing non-random misclassification, which can lead to
overestimation of risks.
It is reassuring that d’Almeira and co-workers report in their
letter that some, limited variation in breast cancer risk estimates
was found with each of the three approaches in the French
material, and that the mothers in this study – as in the Nordic
study – clearly showed a very high risk for breast cancer. In the
Nordic study, we concluded that our data did not convincingly
point to a trend of increasing risk with each increment in the
probability of being a gene carrier, indicating that we should
consider other mechanisms than a genetic one as the cause of
breast cancer in these families. We nevertheless reported a
significantly increased risk for breast cancer among female
relatives below the age of 55 years who had an estimated gene
carrier probability of 0.25, and we acknowledged that the estimated
trend in breast cancer risk by increasing gene carrier probability
was based on a very limited number of outcomes. As pointed out
by d’Almeira and co-workers, international collaboration is the
only means of addressing this problem in an epidemiological
design.
*Correspondence: Dr JH Olsen; E-mail: jorgen@cancer.dk
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